Derbyshire Medicines Management and Clinical Policies
Monotherapy for the treatment of multiple myeloma in adults, who have received ≥4 prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
NHS England drug. To be used in line with NHSE commissioning intentions.
